Biocardia Announces $1.3 Million Registered Direct Offering of Common Stock, Priced at Market Under NASDAQ Rules
BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market SUNNYVALE, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) — BioCardia, Inc. [Nasdaq: BCDA] (the “Company”), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that it has entered into a definitive agreement with a single healthcare-focused…